Masimo, Irvine, Calif, and CareFusion, San Diego, recently signed a multi-year technology licensing agreement establishing the noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry^™ technology to be used in CareFusion infusion and respiratory products under development*.

According to the announcement from Masimo, incorporating the Rainbow SET Pulse CO-Oximetry technology will enable CareFusion's future infusion and respiratory products to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise.

Currently, CareFusion utilizes Masimo technology in its Alaris^® Spo₂ module. The Alaris PCA module together with the Alaris Spo₂ module provides clinicians the ability to automatically pause PCA infusion if a patient falls below hospital-defined respiratory monitoring limits.

"We look forward to a growing technology partnership with CareFusion and the possibilities created by the integration of Masimo Rainbow SET into CareFusion's infusion and respiratory products," said Masimo president of OEM business, Rick Fishel, in the announcement.

*Noted by Masimo in the agreement announcement: “As of the date of the communication, the products under development have not been cleared for commercial sale by the FDA. The products under development may not be cleared for commercial sale by the FDA. The company may not make the products under development available for commercial sale.”